Citigroup
ADCT icon

Citigroup’s ADC Therapeutics ADCT Stock Holding History

Citigroup’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.1K Buy
49,672
+18,002
+57% +$52.5K ﹤0.01% 4955
2026
Q1 		$119K Buy
31,670
+15,561
+97% +$61.3K ﹤0.01% 4216
2025
Q4 		$56.9K Buy
16,109
+12,665
+368% +$51.4K ﹤0.01% 4522
2025
Q3 		$13.8K Sell
3,444
-22,646
-87% -$71.4K ﹤0.01% 4929
2025
Q2 		$69.9K Sell
26,090
-31,556
-55% -$66.4K ﹤0.01% 4591
2025
Q1 		$81.3K Sell
57,646
-6,493
-10% -$11K ﹤0.01% 4705
2024
Q4 		$128K Buy
64,139
+5,237
+9% +$13.7K ﹤0.01% 4703
2024
Q3 		$186K Buy
58,902
+43,479
+282% +$137K ﹤0.01% 4389
2024
Q2 		$48.7K Buy
+15,423
New +$61.3K ﹤0.01% 4596
2023
Q3 		– Sell
-1,834
Closed -$3.94K – 5653
2023
Q2 		$3.94K Buy
+1,834
New +$4.12K ﹤0.01% 5209
2023
Q1 		– Sell
-38
Closed -$146 – 5450
2022
Q4 		$146 Buy
38
+7
+23% +$28 ﹤0.01% 5619
2022
Q3 		$0 Sell
31
-2
-6% -$14 ﹤0.01% 5775
2022
Q2 		$0 Hold
33
– – ﹤0.01% 6186
2022
Q1 		$0 Buy
33
+1
+3% +$16 ﹤0.01% 6273
2021
Q4 		$1K Buy
+32
New +$772 ﹤0.01% 5749

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup's ADCT Position: Q2 2026 in Review

Citigroup increased its ADC Therapeutics (ADCT) stake by 57% in Q2 2026, buying an estimated $52.5K and bringing the position to 49,672 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4955.

Citigroup first reported a position in ADCT in Q4 2021 and has held it in 15 quarters since. The position peaked at $186K in Q3 2024. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Citigroup held 49,672 shares of ADC Therapeutics worth $53.1K as of Q2 2026.
  • Citigroup bought 18,002 ADC Therapeutics shares in Q2 2026, an estimated $52.5K.
  • ADC Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4955 holding.
  • Citigroup first reported a position in ADC Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Citigroup's ADC Therapeutics position peaked at $186K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.